Patents Assigned to Hangzhou Innogate Pharma Co., Ltd.
-
Patent number: 11352353Abstract: A heterocyclic compound which is an inhibitor of FGFR4 (fibroblast growth factor receptor 4) is described. Specifically, a compound represented by the following formula (I), including an isomer (enantiomer or diastereomer) which may be present, or a pharmaceutically acceptable salt thereof, prodrugs, deuterated derivatives, hydrates, solvates, are described. The definition of each group in the formula (I) is as described in the specification. The compounds have FGFR4 inhibitory activity and can be used for the prevention or treatment of diseases associated with FGFR4 activity or expression, and can also be used in combination with other drugs for the treatment of various related diseases, as described.Type: GrantFiled: May 27, 2017Date of Patent: June 7, 2022Assignee: Hangzhou Innogate Pharma Co., Ltd.Inventors: Hancheng Zhang, Shifeng Liu, Xiangyang Ye
-
Patent number: 11266640Abstract: Compounds as IDO inhibitors and/or dual inhibitors of IDO-HDAC are described. Specifically, the compounds represented by the following formula (I) are described, wherein each group is defined as described in the specification. The compounds have IDO inhibitory activity or IDO-HDAC dual inhibitory activity and can be used for preventing or treating diseases associated with IDO and/or IDO-HDAC activity or expression levels. At the same time, the compounds of the present invention can be combined with an anti-tumor antibody such as PD-1 and PD-L1, and such a combination can greatly increase the anti-tumor response rate of the antibody and broaden the types of tumors to be treated.Type: GrantFiled: September 20, 2018Date of Patent: March 8, 2022Assignee: Hangzhou Innogate Pharma Co., Ltd.Inventors: Hancheng Zhang, Xiangyang Ye
-
Patent number: 11225492Abstract: The present invention provides compounds of Formula (I), and the pharmaceutically acceptable salts, hydrates, and solvates thereof. It also provides pharmaceutical compositions, preparation and utilities thereof in treating diseases and disorders including cancers.Type: GrantFiled: December 13, 2016Date of Patent: January 18, 2022Assignee: Hangzhou Innogate Pharma Co., Ltd.Inventors: Hancheng Zhang, Shifeng Liu
-
Patent number: 11142535Abstract: A heterocyclic compound as a Syk inhibitor and/or a Syk-HDAC dual inhibitor, or pharmaceutically acceptable salts, prodrugs, deuterated derivatives, hydrates, and solvates thereof are provided. Specifically, a compound of formula (I) is provided, which has dual inhibitory activity for Syk and/or Syk-HDAC.Type: GrantFiled: December 12, 2017Date of Patent: October 12, 2021Assignee: Hangzhou Innogate Pharma Co., Ltd.Inventors: Hancheng Zhang, Shifeng Liu, Xiangyang Ye, Wenting Chen
-
Patent number: 10968234Abstract: A class of compounds containing a tricyclic heteroaryl group is provided. Specifically, a compound of the structure represented by the following formula (I) (each group is as defined in the specification), a pharmaceutical composition containing the compound of the formula (I), and their isotope derivatives, chiral isomers, allosteries, different salts, prodrugs, preparations, etc, are provided. It can effectively inhibit protein kinases (such as EGFR, FAK, SYK, FLT-3, Axl, CDK, JAK, etc.), thereby treating various tumors, non-alcoholic liver disease (NASH), pulmonary fibrosis (IPF), and related variety of diseases.Type: GrantFiled: July 23, 2020Date of Patent: April 6, 2021Assignee: Hangzhou Innogate Pharma Co., Ltd.Inventors: Hancheng Zhang, Shifeng Liu, Xiangyang Ye
-
Patent number: 10934311Abstract: A heterocyclic compound is described, which is an inhibitor of FGFR (fibroblast growth factor receptor). Specifically, it is a compound represented by the following formula (I), including an isomer (enantiomer or diastereomer) which may be present, or a pharmaceutically acceptable salt thereof, prodrugs, deuterated derivatives, hydrates, solvates. The definition of each group in the formula (I) is as described in the specification. The compound of the present invention has FGFR inhibitory activity and can be used for preventing or treating a disease associated with FGFR activity or expression.Type: GrantFiled: January 9, 2017Date of Patent: March 2, 2021Assignee: Hangzhou Innogate Pharma Co., Ltd.Inventors: Hancheng Zhang, Shifeng Liu
-
Patent number: 10730887Abstract: A class of compounds containing a tricyclic heteroaryl group is provided. Specifically, a compound of the structure represented by the following formula (I) (each group is as defined in the specification), a pharmaceutical composition containing the compound of the formula (I), and their isotope derivatives, chiral isomers, allosterics, different salts, prodrugs, preparations, etc, are provided. It can effectively inhibit protein kinases (such as EGFR, FAK, SYK, FLT-3, Axl, CDK, JAK, etc.), thereby treating various tumors, non-alcoholic liver disease (NASH), pulmonary fibrosis (IPF), and related variety of diseases.Type: GrantFiled: December 12, 2017Date of Patent: August 4, 2020Assignee: Hangzhou Innogate Pharma Co., Ltd.Inventors: Hancheng Zhang, Shifeng Liu, Xiangyang Ye
-
Patent number: 10358451Abstract: Provided are compounds of Formula (I) shown below using for treatment of diseases or disorders mediated by IDO and/or TDO, pharmaceutical compositions and methods of preparation thereof.Type: GrantFiled: April 12, 2016Date of Patent: July 23, 2019Assignee: Hangzhou Innogate Pharma Co., Ltd.Inventors: Hancheng Zhang, Shifeng Liu